Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT00372476
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Imatinib and Vinorelbine — DRUG
Study Details
This study is designed to investigate the safety and efficacy of the combination of imatinib and vinorelbine in patients with advanced, anthracycline resistant breast cancer
Key Dates
- Start date
- Jun 30, 2006
- Status verified
- Feb 2017
- Primary completion
- Jul 31, 2012
- Completion
- Jul 31, 2012
Study Design
- Enrollment
- 33 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Imatinib + Vinorelbine
Primary Outcome Measure
Maximum tolerated dose (MTD) [ Time Frame: at least 28 days ]
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast CancerRecruiting · Carol Fabian, MD · Kansas City, Kansas
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland